Leerink Partners Initiates Coverage of Obsidian Therapeutics with Outperform Rating
Published . Updated .
Fintel reports that on September 22, 2026, Leerink Partners initiated coverage of Obsidian Therapeutics (NASDAQCM:OBX) with a Outperform recommendation. This coverage initiation by Leerink Partners on September 22, 2026, represents the firm's latest quantitative assessment of th
Directly affected
- OBX Obsidian Therapeutics
Named in this report.
Indirectly affected
- UPGD INVESCO BLOOMBERG ANALYST RATING ETF
GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Fintel reports that on September 22, 2026, Leerink Partners initiated coverage of Obsidian Therapeutics (NASDAQCM:OBX) with a Outperform recommendation. This coverage initiation by Leerink Partners on September 22, 2026, represents the fir…
Source: Nasdaq Markets
The price since 22 Sep 2026: Invesco Bloomberg Analyst Rating Etf (UPGD) versus the S&P 500
Since the first closing price after “Leerink Partners Initiates Coverage of Obsidian Therapeutics with Outperform Rating,” Invesco Bloomberg Analyst Rating Etf (UPGD) is +1.45%. The S&P 500 fund (SPY) is -0.17% over the same days, a +1.62% difference versus the market.
Who gains and who loses around Invesco Bloomberg Analyst Rating Etf (UPGD)
Companies tied to this story
- UPGD Invesco Bloomberg Analyst Rating Etf
For “Leerink Partners Initiates Coverage of Obsidian Therapeutics with Outperform Rating,” Invesco Bloomberg Analyst Rating Etf (UPGD) is linked, with no stored direction, medium confidence. Reason on file: GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Invesco Bloomberg Analyst Rating Etf (UPGD)
On 22 Sep 2026, “Leerink Partners Initiates Coverage of Obsidian Therapeutics with Outperform Rating” is the story that connects Invesco Bloomberg Analyst Rating Etf (UPGD) to this story.
Invesco Bloomberg Analyst Rating Etf (UPGD) is on the page because GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Invesco Bloomberg Analyst Rating Etf (UPGD) price range
UPGD traded between 80.14 and 82.00 across 17 sessions. The latest close on file is 82.00.
How strong the case is around Invesco Bloomberg Analyst Rating Etf (UPGD)
14 out of 100
“Leerink Partners Initiates Coverage of Obsidian Therapeutics with Outperform Rating” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.